This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This MAVS antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 477-505 amino acids from the C-terminal region of human MAVS.
MAVS
Reaktivität: Human
WB, ELISA
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
WB: 1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
MAVS Antibody (C-term) can be refrigerated at 2-8 °C for up to 6 months. For long term storage, place the at -20 °C.
Haltbarkeit
6 months
Target
MAVS
(Mitochondrial Antiviral Signaling Protein (MAVS))
Andere Bezeichnung
MAVS
Hintergrund
Double-stranded RNA viruses are recognized in a cell type-dependent manner by the transmembrane receptor TLR3 (MIM 603029) or by the cytoplasmic RNA helicases MDA5 (MIM 606951) and RIGI (ROBO3, MIM 608630). These interactions initiate signaling pathways that differ in their initial steps but converge in the activation of the protein kinases IKKA (CHUK, MIM 600664) and IKKB (IKBKB, MIM 603258), which activate NFKB (see MIM 164011), or TBK1 (MIM 604834) and IKKE (IKBKE, MIM 605048), which activate IRF3 (MIM 603734). Activated IRF3 and NFKB induce transcription of IFNB (IFNB1, MIM 147640). For the TLR3 pathway, the intermediary molecule before the pathways converge is the cytoplasmic protein TRIF (TICAM1, MIM 607601). For RIGI, the intermediary protein is mitochondria-bound IPS1 (Sen and Sarkar, 2005 [PubMed 16239922]).